Bruker Corporation

Bruker Corporation reported second-quarter 2026 revenue of $838.5 million, up 5.2% year-over-year, marking a return to organic growth of 2.8%, or 3.4% excluding U.S. tariff refunds. Non-GAAP earnings per share rose 53% to $0.49, driven by cost-saving actions and a net tariff refund benefit, while GAAP results included a diluted loss per share of $0.41 due to a noncash goodwill impairment charge of $135 million related to automation and spatial biology businesses. The company saw strong bookings, with Scientific Instruments organic orders up 10%, biopharma bookings growing more than 20%, and semiconductor metrology orders surging over 50% organically. Bruker maintained its full-year 2026 non-GAAP EPS guidance of $2.10 to $2.15, representing 15% to 17% growth, and expects fourth-quarter revenue of $1.02 billion to $1.04 billion with meaningful margin expansion.

The ten research tools and consumables stocks tracked reported mixed first-quarter results, with aggregate revenues beating analysts' consensus estimates by 1.3% and next-quarter revenue guidance coming in 2% above expectations. Mettler-Toledo posted revenues of 947.1 million dollars, up 7.2% year on year and slightly ahead of estimates, though the quarter was mixed overall. Waters Corporation stood out with revenues of 1.27 billion dollars, a 91.5% year-on-year surge that exceeded estimates by 4.5%, and it delivered the biggest analyst estimate beat, highest guidance raise, and fastest revenue growth among its peers. Revvity's revenues of 686.9 million dollars, up 9.3% year on year, missed estimates by 2.6% and it issued full-year guidance below expectations, marking the weakest performance against estimates in the group. Sotera Health Company reported revenues of 280 million dollars, up 10% year on year and beating estimates by 3.6%, while Bruker's revenues of 823.4 million dollars, up 2.7% year on year, topped estimates by 3.4%. Share prices of the group have risen 20.8% on average since the latest earnings results.

JPMorgan maintained an Overweight rating on Bruker Corporation and raised its price target to $65 from $45. Analyst Casey Woodring updated the company model on June 8. The move follows Bruker's presentation of advances in its microbiology and infection diagnostics portfolio at ASM Microbe 2026, including FDA-approved updates to its MALDI Biotyper CA System that now identifies 549 clinically validated microbial species. The company also introduced research-use tools with libraries covering 5,325 species and is developing a rapid antimicrobial susceptibility testing workflow.

Shares of scientific instrument company Bruker jumped 4.2% in morning trading after Barclays raised its price target to $60 and reiterated an Overweight rating. The optimism was driven by Bruker's new mass spectrometry and proteomics products showcased at the ASMS conference, along with a new shelf registration that increases financial flexibility for potential future deals. The stock cooled to $60.87, up 4.2% from the previous close, and is trading near its 52-week high of $62.70.

The research tools and consumables industry reported mixed first-quarter results, with aggregate revenues beating analyst consensus estimates by 1.3% and next-quarter revenue guidance coming in 2% above expectations. Avantor posted flat revenues of $1.58 billion, exceeding estimates by 2.7%, while Waters Corporation saw revenues surge 91.5% to $1.27 billion, the fastest growth among peers. Revvity's revenues rose 9.3% to $686.9 million but missed estimates by 2.6%, and Bruker's revenues grew 2.7% to $823.4 million, topping expectations by 3.4%. Danaher reported a 3.7% revenue increase to $5.95 billion, slightly missing estimates by 0.8%. Share prices across the group have risen an average of 8.5% since the latest earnings releases.

Bruker Corporation has seen its shares rise 50.3% over the past year, outpacing the industry's 42.5% gain and the S&P 500's 28.2% increase. The rally has been driven by strong growth in the BSI NANO segment, where AI-fueled demand for memory chips and advanced packaging pushed semi-metrology revenues above $300 million annually, and by market share gains in preclinical imaging, highlighted by the acceptance of an 18 Tesla preclinical MRI system in the first quarter of 2026. The company repaid $181.3 million of long-term debt, reducing the balance to $1.66 billion, and net leverage declined to 2.9 times. However, adjusted operating margin fell to 10.2% from 12.7% a year earlier, partly due to tariffs and foreign exchange, which reduced adjusted earnings per share by $0.05 in the quarter. The Zacks Consensus Estimate for 2026 earnings per share remains at $2.12, with a long-term growth rate of 14.8%.